Abstract：【Objective】Objective To observe the curative effect of acitinib combined with radical operation on senile renal cell carcinoma before operation. 【Methods】A total of 120 elderly patients with renal cell carcinoma were randomly divided into observation group and control group, with 60 cases in each group. The patients in the control group were treated with endoscopic radical nephrectomy. The patients in the observation group were treated with the molecular targeted drug of renal cancer, acitinib, before the radical nephrectomy. After taking the drug for one month, the surgery was performed. The therapeutic effects, tumor markers [CEA, NSE, pro gastrin releasing peptide (pro-GRP), and vascular endothelial growth factor (VEGF)] levels of the two groups were compared Immune index [T lymphocyte (CD3+, CD4+, CD8+)] level, 3-year survival rate and adverse reactions.【Results】After one month of treatment, the objective remission rate of the observation group was significantly higher than that of the control group(P<0.05);The levels of CEA, NSE, pro-GRP and VEGF in the two groups after treatment were significantly lower than those before treatment (P<0.05); The observation group was significantly lower than the control group (P<0.05); After treatment, the levels of CD3+, CD4+, CD4+/CD8+ in both groups were significantly higher than those before treatment (P<0.05), CD8+ was significantly lower than that before treatment (P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ in the observation group were significantly higher than those in the control group, and the levels of CD8+ were significantly lower than those in the control group (P<0.05); The PFS and OS of the observation group were significantly better than those of the control group (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The preoperative application of acitinib can effectively promote tumor remission, improve the radical operation and improve the prognosis, and improve the immune function and tumor marker level of patients, without increasing the incidence of adverse reactions.
2022, Vol. 39 
